HC Wainwright Brokers Reduce Earnings Estimates for CTMX

Key Points

• HC Wainwright has downgraded its Q3 2025 EPS estimate for CytomX Therapeutics from $0.02 to $0.00, while maintaining a "Buy" rating with a $5.00 price target.
• Other analysts have varied ratings on the stock, with Wedbush setting a price target of $6.00 and Piper Sandler increasing their target to $5.00, contributing to an average price target of $5.75.
• The stock opened at $2.31 with a market cap of $186.23 million, and has had significant hedge fund interest, with institutional investors owning approximately 67.77% of the company's stock.

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings per share estimates for CytomX Therapeutics in a research report issued on Monday, August 11th. HC Wainwright analyst M. Kapoor now forecasts that the biotechnology company will earn $0.00 per share for the quarter, down from their prior estimate of $0.02. HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for CytomX Therapeutics' Q4 2025 earnings at $0.00 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.00 EPS and Q3 2026 earnings at ($0.01) EPS.

A number of other equities analysts have also weighed in on the company. Wall Street Zen raised CytomX Therapeutics from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th. Piper Sandler boosted their target price on CytomX Therapeutics from $2.50 to $5.00 and gave the company an "overweight" rating in a research report on Thursday, May 15th. Oppenheimer assumed coverage on CytomX Therapeutics in a research report on Thursday, July 31st. They set an "outperform" rating and a $7.00 target price on the stock. Finally, Wedbush restated an "outperform" rating and set a $6.00 price objective (up previously from $5.00) on shares of CytomX Therapeutics in a report on Monday, May 12th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $5.75.

CytomX Therapeutics Stock Up 8.5%

CTMX traded up $0.15 during midday trading on Tuesday, reaching $1.91. The company had a trading volume of 9,885,213 shares, compared to its average volume of 2,678,026. The business has a 50-day moving average of $2.34 and a two-hundred day moving average of $1.49. The company has a market cap of $153.99 million, a P/E ratio of 3.41 and a beta of 2.13. CytomX Therapeutics has a 1 year low of $0.40 and a 1 year high of $3.10.

Institutional Investors Weigh In On CytomX Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. grew its stake in shares of CytomX Therapeutics by 288,736.3% during the fourth quarter. JPMorgan Chase & Co. now owns 811,630 shares of the biotechnology company's stock worth $836,000 after acquiring an additional 811,349 shares during the last quarter. Renaissance Technologies LLC lifted its stake in CytomX Therapeutics by 32.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,346,800 shares of the biotechnology company's stock valued at $1,387,000 after acquiring an additional 331,800 shares during the period. Millennium Management LLC boosted its holdings in shares of CytomX Therapeutics by 25.8% in the 4th quarter. Millennium Management LLC now owns 3,221,012 shares of the biotechnology company's stock valued at $3,318,000 after acquiring an additional 660,756 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in shares of CytomX Therapeutics by 18.6% in the first quarter. Assenagon Asset Management S.A. now owns 711,454 shares of the biotechnology company's stock worth $452,000 after acquiring an additional 111,604 shares during the period. Finally, Northern Trust Corp increased its stake in shares of CytomX Therapeutics by 16.0% in the fourth quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company's stock worth $155,000 after acquiring an additional 20,746 shares during the period. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.